Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. (1st November 2021)
- Record Type:
- Journal Article
- Title:
- Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. (1st November 2021)
- Main Title:
- Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort
- Authors:
- Granger, Luke A.
Huettner, Isabella
Debeljak, Franka
Kaleebu, Pontiano
Schechter, Mauro
Tambussi, Giuseppe
Weber, Jonathan
Miro, Jose M.
Phillips, Rodney
Babiker, Abdel
Cooper, David A.
Fisher, Martin
Ramjee, Gita
Fidler, Sarah
Frater, John
Fox, Julie
Doores, Katie J. - Abstract:
- Abstract : Objective: Development of immunogens that elicit an anti-HIV-1 broadly neutralizing antibody (bnAb) response will be a key step in the development of an effective HIV-1 vaccine. Although HIV-1 bnAb epitopes have been identified and mechanisms of action studied, current HIV-1 envelope-based immunogens do not elicit HIV-1 bnAbs in humans or animal models. A better understanding of how HIV-1 bnAbs arise during infection and the clinical factors associated with bnAb development may be critical for HIV-1 immunogen design efforts. Design and methods: Longitudinal plasma samples from the treatment-naive control arm of the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) primary HIV-1 infection cohort were used in an HIV-1 pseudotype neutralization assay to measure the neutralization breadth, potency and specificity of bnAb responses over time. Results: In the SPARTAC cohort, development of plasma neutralization breadth and potency correlates with duration of HIV infection and high viral loads, and typically takes 3–4 years to arise. bnAb activity was mostly directed to one or two bnAb epitopes per donor and more than 60% of donors with the highest plasma neutralization having bnAbs targeted towards glycan-dependent epitopes. Conclusion: This study highlights the SPARTAC cohort as an important resource for more in-depth analysis of bnAb developmental pathways. Abstract : Supplemental Digital Content is available in the text
- Is Part Of:
- AIDS. Volume 35:Number 13(2021)
- Journal:
- AIDS
- Issue:
- Volume 35:Number 13(2021)
- Issue Display:
- Volume 35, Issue 13 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 13
- Issue Sort Value:
- 2021-0035-0013-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-11-01
- Subjects:
- broadly neutralizing antibody -- HIV-1 -- longitudinal -- vaccine
AIDS (Disease) -- Periodicals
Acquired Immunodeficiency Syndrome
AIDS (Disease)
Periodicals
Periodicals
616.9792005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=00002030-000000000-00000 ↗
http://journals.lww.com/aidsonline/pages/default.aspx?desktopMode=true ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/QAD.0000000000002988 ↗
- Languages:
- English
- ISSNs:
- 0269-9370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0773.083000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 20278.xml